Comparison Chart Annexin Pharmaceuticals AB

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 08:30:00 2026-10-30 EDT			5-day change	1st Jan Change
6.640 ^SEK	-0.90%		-14.21%	-66.46%

10-22	Annexin Enrolls Last Patient in Mid-stage Trial of Eye Disease Drug Candidate	MT
10-22	Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	ANNEXIN PHARMACEUTICALS AB	Bio Therapeutic Drugs	-0.90%	-14.21%	-66.46%	-73.44%	-94.68%	5.89M